Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
eRNA therapeutic encoding functional full-length cystic fibrosis transmembrane conductance regulator (CFTR) protein. It is being evaluated in preclinical development for the treatment of Cystic Fibrosis.
Lead Product(s): eRNA-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
The net proceeds will be used to advance Sail’s first-in-category Endless RNA™ platform for preclinical development of an eRNA-based vaccines and to develop secreted monoclonal antibodies (mAbs) for malaria.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 03, 2024